SCHEDULE: Frazier Life Sciences Exits Macrogenics Stake

Frazier Life Sciences and its affiliates have reported a complete divestment of their beneficial ownership in Macrogenics, Inc., holding 0.0% of common stock.

Summary

• Frazier Life Sciences Public Fund, L.P., along with several affiliated entities and individuals including James N. Topper and Patrick J. Heron, have filed an Amendment No. 2 to Schedule 13G.
• The filing indicates that as of December 31, 2025, the reporting persons collectively hold 0.00 shares of Macrogenics, Inc. common stock.
• This represents 0.0% of the class of securities, signifying a complete divestment of their previously held stake.
• The reporting group certified that the securities were not acquired or held for the purpose of changing or influencing control of Macrogenics, Inc.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative development for Macrogenics, Inc., as the complete exit of a specialized life sciences investor group could signal diminished confidence in the company's future performance or strategic direction.

Positives

• The reporting persons certified that their previous holdings were not for the purpose of changing or influencing control of Macrogenics, Inc.

Negatives

• A significant institutional investor group, Frazier Life Sciences, has fully divested its stake in Macrogenics, Inc.
• The complete exit of a major investor could signal a loss of confidence in the company's future prospects or strategy.

Risks

• The divestment by a prominent life sciences investor group might be interpreted negatively by the market, potentially leading to downward pressure on Macrogenics' stock price.
• Loss of institutional support from a specialized life sciences fund could impact future capital-raising efforts or investor relations.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding Macrogenics, Inc.'s future outlook.

Industry Context

StockSavvy.ai notes that the complete divestment by Frazier Life Sciences, a prominent investor in the life sciences sector, could be viewed by the market as a significant signal regarding Macrogenics' long-term potential or current operational challenges. Such exits by specialized funds often prompt other investors to re-evaluate their positions, especially in the volatile biotechnology industry where investor confidence is crucial.

Comparison to Industry Standards

• The divestment by Frazier Life Sciences, a well-known venture capital and growth equity firm focused on healthcare, suggests a strategic re-allocation of capital away from Macrogenics.
• In the biotechnology sector, institutional investor exits can sometimes precede periods of underperformance or reflect concerns about pipeline development, regulatory hurdles, or competitive landscape, similar to how other biotech companies might see investor sentiment shift following clinical trial results or major partnership announcements.

Stakeholder Impact

• Shareholders: Existing shareholders may interpret the divestment as a negative indicator, potentially leading to a decrease in share price. Potential investors might be deterred by the exit of a sophisticated life sciences fund.

Key Dates

Recommendation

The complete divestment by a significant and specialized institutional investor group like Frazier Life Sciences suggests a lack of confidence in Macrogenics' future prospects. This action by a sophisticated investor often signals potential headwinds or a re-evaluation of the company's investment thesis, making a "sell" recommendation prudent for investors seeking to avoid potential downside risk.

Keywords

Macrogenics, MGEN, Frazier Life Sciences, Schedule 13G, beneficial ownership, divestment, institutional investor, common stock, SEC filing, biotech, pharmaceutical